USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ANGION BIOMEDICA CORPORATION
City: Uniondale
State: NY
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $10,629,917.00 45
SBIR Phase II $47,035,594.00 24

Award List:

THERAPEUTIC ANGIOGENESIS BY SF/HGF GENE TRANSFER

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter F. Mento
Award Amount: $99,975.00
Abstract:
Not Available High Cycle Fatigue (HCF) is affecting aircraft system readiness, operability and cost of ownership. State-of-the-art passive damping treatments, while effective, are limited to temperatures below 500 degrees F and to static structures. The needs and environment posed by gas turbine… More

ADENOVIRUS SF TRANSDUCTION FOR ANGIOGENIC GENE THERAPY

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter F. Mento
Award Amount: $108,600.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter F. Mento
Award Amount: $115,754.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter F. Mento
Award Amount: $117,834.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter F. Mento
Award Amount: $118,096.00

RENAL INJURY PREVENTION BY SF/HGF-LIKE SMALL MOLECULES

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter F. Mento
Award Amount: $106,822.00
Abstract:
DESCRIPTION (provided by applicant): Recent studies support the concept that treatment with scatter factor/hepatocyte growth factor can prevent renal dysfunction in mouse models of renal failure. SF/HGF has multiple actions such as proliferative, pro-fibrinolytic and anti-apoptotic activities that… More

ANTI-ANGIOGENIC & ANTI-TUMOR DRUG FOR HUMAN GLIOMA

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter F. Mento
Award Amount: $493,120.00
Abstract:
Numerous novel approaches to cancer therapy are currently being examined including gene therapy, immunotherapy and combinations of traditional and novel therapies. By targeting multiple events in the proliferation and spread of cancer cells the effectiveness of treatments may be improved and… More

SF/HGF GENE TRANSFER FOR PERIPHERAL ISCHEMIA

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter F. Mento
Award Amount: $0.00
Abstract:
Cardiovascular disease is the leading cause of morbidity and mortality in the US, afflicting over 58 million Americans. Angiogenic factors can increase vascularization and improve perfusion in ischemia. Scatter factor/hepatocyte growth factor (SF/HGF) may be superior to other angiogenic factors… More

SF/HGF GENE TRANSFER FOR PERIPHERAL ISCHEMIA

Award Year / Program / Phase: 2002 / SBIR / Phase II
Agency: HHS
Principal Investigator: Peter F. Mento
Award Amount: $1,859,167.00
Abstract:
Cardiovascular disease is the leading cause of morbidity and mortality in the US, afflicting over 58 million Americans. Angiogenic factors can increase vascularization and improve perfusion in ischemia. Scatter factor/hepatocyte growth factor (SF/HGF) may be superior to other angiogenic factors… More

Renal Injury Prevention by SF/HGF-like Small Molecules

Award Year / Program / Phase: 2003 / SBIR / Phase II
Agency: HHS
Principal Investigator: Parakash Narayan
Award Amount: $2,827,834.00
Abstract:
DESCRIPTION (provided by applicant): Chronic renal dysfunction is a progressive, degenerative disorder that ultimately results in acute renal failure and requires dialysis as an intervention, and renal transplantation as the only potential cure. Initiating conditions of renal dysfunction include… More

Anti-apoptotic Mechanism of SF/HGF Mimetics

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Prakash Narayan
Award Amount: $191,709.00
Abstract:
DESCRIPTION (provided by applicant): Apoptotic cell loss triggered by ischemia-reperfusion plays a prominent role in delayed graft function and acute renal failure following kidney transplant. In experimental models of ischemia-reperfusion, treatment with scatter factor/hepatocyte growth factor… More

Hepatocyte Growth Factor Mimetic for Liver Fibrosis

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter F. Mento
Award Amount: $190,321.00
Abstract:
DESCRIPTION (provided by applicant): Hepatic fibrosis, a disease affecting tens of millions of patients worldwide, is the liver scarring response that occurs in response to chronic injury from viral hepatitis B or C, excessive alcohol use, and iron overload, and often leads to liver failure and… More

Protection from Atherosclerosis by c-Met Agonist

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Latha Paka
Award Amount: $197,752.00
Abstract:
DESCRIPTION (provided by applicant): Activation of cell death pathways leading to endothelial cell apoptosis and neointimal vascular smooth muscle cell hyperplasia is an initial trigger of the progression of atherosclerotic lesions. Because apoptosis is a highly regulated cellular process and… More

Refanalin for Liver Transplantation

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency: HHS
Principal Investigator: Weizhong Cai
Award Amount: $1,398,781.00
Abstract:
DESCRIPTION (provided by applicant): Orthotopic liver transplantation is the most effective treatment for patients with end-stage liver disease. Ischemia-reperfusion injury associated with the retrieval, storage and transplantation of livers is a major immune-independent factor adversely… More

Hepatic Growth Factor Mimetic for Liver Fibrosis

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency: HHS
Principal Investigator: Weizhong Cai
Award Amount: $2,045,157.00
Abstract:
DESCRIPTION (provided by applicant): Hepatic fibrosis, a disease affecting tens of millions of patients worldwide, is the liver scarring response to chronic injury from viral hepatitis B or C, excessive alcohol use, iron overload or extrahepatic obstructions and can progress to liver cirrhosis,… More

Kidney Preservation for Transplantation

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Prakash Narayan
Award Amount: $239,795.00
Abstract:
DESCRIPTION (provided by applicant): Renal transplantation is the most effective and cost efficient treatment for patients with established renal disease. However ischemia-reperfusion injury associated with the retrieval, storage and transplantation of kidneys from cadavers is a major… More

Therapeutic Potential of Refanalin in Pulmonary Fibrosis

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Latha Paka
Award Amount: $175,272.00
Abstract:
DESCRIPTION (provided by applicant): Idiopathic pulmonary fibrosis (IPF) is a devastating disease with less than a 50% five-year survival. While steroids and other immunosuppressive agents serve as the standard treatment for IPF, these agents have proved inadequate and have adverse side effects.… More

Protection from Stroke by SF/HGF-like Small Molecule

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Prakash Narayan
Award Amount: $210,504.00
Abstract:
DESCRIPTION (provided by applicant): Atherosclerosis of the cerebral vasculature can produce occlusion and cerebral infarction. Although the tissue in the ischemia core dies within minutes, the surrounding tissue, termed the ischemic penumbra, sustains damage from cytotoxic factors including… More

Small Molecule Therapeutics for Myocardial Ischemia

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Prakash Narayan
Award Amount: $225,829.00
Abstract:
DESCRIPTION (provided by applicant): Left untreated, myocardial ischemia can lead to cardiomyocte death and pump failure. In fact, ischemic heart disease is a significant cause of morbidity and mortality in the U.S. Recent evidence suggests that scatter factor / hepatocyte growth factor, exerts… More

Anti-Fibrotic Therapy for Pulmonary Fibrosis

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Latha Paka
Award Amount: $1,874,410.00
Abstract:
DESCRIPTION (provided by applicant): Pulmonary Fibrosis is a diffuse interstitial lung disease characterized by chronic inflammation and progressive fibrosis of unknown etiology. Pulmonary fibrosis affects five million people worldwide and in the United States there are over 200,000 patients with… More

Small Molecule Therapeutics for Myocardial Ischemia

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Prakash Narayan
Award Amount: $1,563,729.00
Abstract:
DESCRIPTION (provided by applicant): Left untreated, myocardial ischemia can lead to cardiomyocyte death and pump failure. In fact, myocardial infarction is a significant cause of morbidity and mortality in the U.S. Recent evidence suggests that scatter factor / hepatocyte growth factor, exerts… More

Novel Small Molecule Therapeutic for Spinal Cord Injury

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Alexander Yuzhakov
Award Amount: $203,973.00
Abstract:
DESCRIPTION (provided by applicant): It is estimated that the annual incidence of spinal cord injury (SCI), not including those who die at the scene of the accident, is approximately 11,000 cases each year. The number of living patients in the United States as of December 2003 who have SCI, has… More

Kidney Preservation for Transplantation

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Prakash Narayan
Award Amount: $2,034,829.00
Abstract:
DESCRIPTION (provided by applicant): Renal transplantation is the most effective and cost-efficient treatment for patients in end-stage kidney failure. However ischemia-reperfusion injury, associated with the retrieval, storage and transplantation of kidneys is a major immune-independent factor… More

Novel Small Molecules For Acute Liver Failure

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Prakash Narayan
Award Amount: $254,257.00
Abstract:
DESCRIPTION (provided by applicant): Acute liver failure (ALF) constitutes a challenge to clinicians and scientists alike. Commonly associated with the alcohol-acetaminophen syndrome, its clinical course is unpredictable and polarizing, with death as the o utcome in a large percentage of cases.… More

Small Molecule Therapeutics for Renal Disease

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Prakash Narayan
Award Amount: $264,578.00
Abstract:
DESCRIPTION (provided by applicant): Progressive renal disease remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition that necessitates renal replacement therapy. Few, if a ny, of the currently practiced therapeutic… More

Refanalin for lung preservation and transplantation

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Weizhong Cai
Award Amount: $254,535.00
Abstract:
DESCRIPTION (provided by applicant): Lung transplantation has become the mainstay of therapy for most end stage lung diseases including pulmonary emphysema, cystic fibrosis, and idiopathic pulmonary fibrosis. However, increasing demand for suitable donor l ungs far exceeds the number of available… More

Novel c-Met and Tie-2 antagonists against human glioma

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Youzhi Tong
Award Amount: $183,826.00
Abstract:
DESCRIPTION (provided by applicant): Malignant glioma is the most commonly diagnosed primary brain cancer. Despite advances in diagnosis and therapy, these tumors show a high incidence of recurrence, have a poor prognosis and lack effective therapies. Rece nt advances in tumor molecular biology have… More

Small Molecule Anti-Fibrotic Therapy for Scleroderma

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Latha Paka
Award Amount: $215,956.00
Abstract:
DESCRIPTION (provided by applicant): Scleroderma or fibrosis of skin caused by a surplus of extracellular matrix protein (collagen) is localized in the skin, or excess collagen may be collected in the kidneys, lungs, gastrointestinal tract, and heart. Scle roderma affects approximately 400,000… More

Small Molecule Therapeutic for Rheumatoid Arthritis

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: David E. Smith
Award Amount: $231,264.00
Abstract:
DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is a chronic disease, characterized mainly by inflammation of the lining, or synovium, of the joints. It can lead to long-term joint damage, resulting in chronic pain, loss of function and dis ability. Approximately 2.1 million people… More

Novel Small Molecule Therapeutic for Spinal Cord Injury

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: Prakash Narayan
Award Amount: $1,822,130.00
Abstract:
DESCRIPTION (provided by applicant): It is estimated that the annual incidence of spinal cord injury (SCI), not including persons who die at the scene of the accident, is approximately 11,000 cases per year. The number of patients currently affected by SCI in the United States has been estimated at… More

Anti-Angiogenic and Tumorcidal Drugs Against Lung Carcinoma

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $200,594.00
Abstract:
DESCRIPTION (provided by applicant): Lung cancer is the world's leading cause of cancer deaths, with conventional therapies offering very limited benefit. Therefore, novel therapeutic approaches to improve outcomes of this disease are critical. Recent adva nces in tumor cell biology have led to… More

TGFb1 Receptor Inhibitors for Liver Fibrosis

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Weizhong Cai
Award Amount: $255,501.00
Abstract:
DESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of patients worldwide, is the liver scarring response to chronic injury from viral hepatitis B or C, excessive alcohol use, iron overload or extrahepatic obstructions and can progress to liver cirrhosis, liver… More

PARP-1 Inhibitors as Therapy for the Treatment of Stroke

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $229,277.00
Abstract:
DESCRIPTION (provided by applicant): Stroke is leading cause of morbidity and mortality in the US. Research on the pathophysiological basis of stroke has produced new paradigms for prevention and treatment, but translation of these approaches into improved clinical outcomes has proved to be… More

Refanalin for lung preservation and transplantation

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator: Weizhong Cai
Award Amount: $2,075,083.00
Abstract:
DESCRIPTION (provided by applicant): Lung transplantation is the only effective treatment modality for patients with end-stage lung disease. Ischemia-reperfusion injury, associated with the retrieval, storage and transplantation of the lung is a major immu ne-independent factor adversely affecting… More

Novel Therapeutic for Amyotrophic Lateral Sclerosis (ALS)

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $184,012.00
Abstract:
DESCRIPTION (provided by applicant): Literature indicates that HGF via its cytoprotective and tissue-regenerative activities protects a number of organs against traumatic and/or ischemic injury and fibrotic/degenerative disease. We have evaluated the effec ts of BB3/Rf in preclinical models of… More

Therapeutic Potential of a Small Molecule Compound for Emphysema

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $234,658.00
Abstract:
DESCRIPTION (provided by applicant): Emphysema is a major cause of death and disability afflicting approximately 2 million people, costing more than 2.5 billion in yearly health care expenses and causing or contributing to 100,000 deaths per year in the U nited States alone. The disease is… More

Phase I Clinical Trial for BB3

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Weizhong Cai
Award Amount: $295,478.00
Abstract:
DESCRIPTION (provided by applicant): Percutaneous coronary intervention has become the mainstay for treatment of ST-segment elevation myocardial infarction (STEMI). Whereas early recanalization undoubtedly salvages myocardial tissue, reperfusion following prolonged ischemia exacerbates injury.… More

Novel Small Molecule Adjuvants to Drug-eluting Stents

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Prakash Narayan
Award Amount: $295,467.00
Abstract:
DESCRIPTION (provided by applicant): Currently approved drug-eluting stents are plagued by late-stage thrombosis and delayed restenosis. Acceleration of stent re-endothelialization can suppress neointimal hyperplasia, promote healing of the vessel wall, an d decrease restenosis rates. Scatter… More

Novel therapeutic for Alcoholic Liver Disease

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bert J. Oehlen
Award Amount: $327,272.00
Abstract:
DESCRIPTION (provided by applicant): Alcoholic Liver Disease (ALD) is a progressive liver disease that in advanced stages can result in cirrhosis and liver failure. ALD can be divided in various stages of development: (1) mild alcoholic liver injury, (2) s teatosis, (3) alcoholic hepatitis, (4)… More

Small Molecule Therapeutics for Renal Disease

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Prakash Narayan
Award Amount: $1,935,431.00
Abstract:
DESCRIPTION (provided by applicant): Diabetic and non-diabetic nephropathies and the Metabolic Syndrome are associated with chronic kidney disease (CKD) - a program comprising proteinuria, accumulation of profibrotic collagen in the renal interstitium and relentless decline in renal function. CKD… More

Phase I Study of BB3 in Dialysis Patients

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Weizhong Cai
Award Amount: $290,570.00
Abstract:
DESCRIPTION (provided by applicant): Kidney transplantation is the most effective therapeutic modality for end-stage renal disease; it offers a better quality of life and a longer survival. Despite improvements in surgical and organ preservation techniques over the last decade, renal dysfunction… More

Novel Therapeutic for Duchenne Muscular Dystrophy (DMD)

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: David E. Smith
Award Amount: $200,506.00
Abstract:
DESCRIPTION (provided by applicant): A significant body of literature indicates that Hepatocyte Growth Factor (HGF) via potent and direct anti-fibrotic activity protects many organs from the fibrosis-driven pathology. In addition, HGF has been shown to a lso promote muscle progenitor cells to… More

Novel Neuroprotective/Restorative Therapy for Ischemic Stroke

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: David E. Smith
Award Amount: $2,297,251.00
Abstract:
DESCRIPTION (provided by applicant): Ischemic Stroke continues to be a major cause of morbidity and mortality in the United States. Currently approved thrombolytic therapy suffers for a narrow therapeutic window and clearly other therapeutic strategies are needed, such as neuroprotective or… More

Therapeutic use of small-molecule HGF-mimetic for emphysema

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Bert J. Oehlen
Award Amount: $2,089,484.00
Abstract:
DESCRIPTION (provided by applicant): Emphysema is a major cause of death and disability and afflicts approximately 2 million people. The disease cost more than 2.5 billion in annual health care expenses and causes or contributes to the death of 100,000 pe ople each year in the United States alone.… More

Novel Neuroprotective/Anti-inflammatory Therapy for Ischemic Stroke

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: David E. Smith
Award Amount: $2,176,571.00
Abstract:
DESCRIPTION (provided by applicant): Stroke is leading cause of morbidity and mortality in the US. Research on the pathophysiological basis of stroke has produced new paradigms for prevention and treatment, but translation of these approaches into improved clinical outcomes has proved to be… More

Novel Therapy for Amyotrophic Lateral Sclerosis

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: David E. Smith
Award Amount: $1,452,415.00
Abstract:
DESCRIPTION (provided by applicant): Literature indicates that HGF via its cytoprotective and tissue-regenerative activities protects a number of organs against traumatic and/or ischemic injury and fibrotic/degenerative disease. We have evaluated the effec ts of Refanalin/BB3 in preclinical models… More

Safety and PK Study in Hepatic Impairment Patients

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Weizhong Cai
Award Amount: $2,979,147.00
Abstract:
DESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of patients worldwide, is the liver scarring response to chronic injury from viral hepatitis B or C, excessive alcohol use, iron overload or extrahepatic obstructions and can… More

Pilot Clinical Study in Renal Transplantation

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Weizhong Cai
Award Amount: $1,664,287.00
Abstract:
DESCRIPTION (provided by applicant): Kidney transplantation is the most effective therapeutic modality for end-stage renal disease. Given the increasing demand for donor kidneys, more centers today are transplanting kidneys that were previously considered unsuitable. Extended donor kidneys include… More

A Pilot Clinical Study in Acute STEMI

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Weizhong Cai
Award Amount: $2,914,839.00
Abstract:
DESCRIPTION (provided by applicant): Percutaneous coronary intervention (PCI) has become the mainstay for treatment of ST-segment elevation myocardial infarction (STEMI). Whereas early recanalization undoubtedly salvages myocardial tissue, reperfusion foll owing prolonged ischemia can also… More

Anti-Fibrotic Therapy for Scleroderma/SSc

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Latha Paka
Award Amount: $287,606.00
Abstract:
DESCRIPTION (provided by applicant): Scleroderma (also known as systemic sclerosis-SSc) is an autoimmune disorder characterized primarily by progressive dermal and vascular fibrosis. Other organs are affected too, including lung, heart, esophagus, intestin e, and kidney. Many patients who suffer… More

Therapeutic Potential of PARP inhibitor for Acute Pancreatitis

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Latha Paka
Award Amount: $219,145.00
Abstract:
DESCRIPTION (provided by applicant): Acute Pancreatitis (AP) is a potentially lethal inflammatory disease of the pancreas. Its pathogenesis remains obscure and is involved in a process of acute inflammation and necrosis in the pancreas, with variable invol vement of regional tissues or organ systems… More

Phase I Clinical Study Using an Antifibrotic Drug

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Weizhong Cai
Award Amount: $311,292.00
Abstract:
DESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of people worldwide, is the liver scarring response to chronic injury from excessive alcohol use, virus infection (hepatitis B and C), iron overload or extrahepatic o bstructions and can progress to liver… More

Treatment for alcoholic liver disease

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bert J. Oehlen
Award Amount: $238,482.00
Abstract:
DESCRIPTION (provided by applicant): Liver fibrosis is a form of scar formation that is found in almost all patients with chronic injury to the liver. Over time it frequently progresses to cirrhosis, an end-stage lethal disease which is the seventh leading cause of death in the United States and… More

A Novel Therapeutic for Chronic Kidney Disease

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Prakash Narayan
Award Amount: $391,296.00
Abstract:
DESCRIPTION: Chronic kidney disease (CKD) remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition that necessitates renal replacement therapy. Current therapeutic strategies for the treatment of CKD include changes… More

Antifibrotic Therapy for Chronic Kidney Disease

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Prakash Narayan
Award Amount: $271,934.00
Abstract:
DESCRIPTION (provided by applicant): Chronic kidney disease remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition that necessitates renal replacement therapy. Few, if any, of the currently practiced therapeutic… More

PDGFR and KDR Inhibitors for Liver Fibrosis

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Weizhong Cai
Award Amount: $269,786.00
Abstract:
DESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of patients worldwide, is the liver scarring response to chronic injury from viral hepatitis B or C, excessive alcohol use, iron overload or extrahepatic obstructions and can progress to liver cirrhosis, liver… More

Treatment for alcoholic liver disease

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Bert J. Oehlen – 516-326-1200
Award Amount: $2,052,340.00
Abstract:
DESCRIPTION (provided by applicant): Liver fibrosis is a form of scar formation that is found in almost all patients with chronic injury to the liver. Over time it frequently progresses to cirrhosis, an end-stage lethal disease which is the seventh leadingcause of death in the United States and… More

Unique Clinical Study on DGF Using Paired Kidneys

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Weizhong Cai – 516-326-1200
Award Amount: $1,335,726.00
Abstract:
DESCRIPTION: Renal transplantation is the most effective and cost-efficient form of renal replacement therapy for a burgeoning population that presents with end-stage renal disease. Although organ donation has become a national priority, the gap between the number of patients awaiting a kidney vs.… More

Phase I Clinical Study Using an Antifibrotic Drug

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Weizhong Cai – 516-326-1200
Award Amount: $764,642.00
Abstract:
DESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of people worldwide, is the liver scarring response to chronic injury from excessive alcohol use, virus infection (hepatitis B and C), iron overload or extrahepatic obstructions and can progress to liver… More

A Novel Therapeutic for Liver Fibrosis

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Prakash Narayan – 516-326-1200
Award Amount: $269,158.00
Abstract:
DESCRIPTION (provided by applicant): Alcoholic and non-alcoholic liver fibrosis remains an unsolved challenge for the hepatologist as it can lead to cirrhosis and end-stage liver disease, a life-threatening condition that necessitates liver transplantation. Current therapeutic strategies for the… More

A Novel Therapeutic for Liver Fibrosis

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Prakash Narayan – 516-326-1200
Award Amount: $2,087,768.00
Abstract:
DESCRIPTION (provided by applicant): Alcoholic and non-alcoholic liver fibrosis remains an unsolved challenge for the hepatologist as it can lead to cirrhosis and end-stage liver disease, a life-threatening condition that necessitates liver transplantation. Current therapeutic strategies for the… More

Anti-Fibrotic Therapy for Scleroderma/SSc

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Latha Paka – 516-562-1278
Award Amount: $2,809,486.00
Abstract:
DESCRIPTION (provided by applicant): Scleroderma (also known as systemic sclerosis-SSc) is characterized primarily by progressive dermal and vascular fibrosis. Other organs are affected too, including lung, heart, blood vessels, GI and kidney. Many patients who suffer from scleroderma/SSc also have… More

Antifibrotic Therapy for Chronic Kidney Disease

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Prakash Narayan – 516-326-1200
Award Amount: $1,780,804.00
Abstract:
DESCRIPTION (provided by applicant): Chronic kidney disease (CKD) remains an unsolved challenge for the nephrologist, as it almost inevitably leads to end-stage renal failure, a life-threatening condition that necessitates renal replacement therapy. Few, if any, of the currently practiced… More

Novel Neuroprotective/Restorative Therapy for Ischemic Stroke

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: David E. Smith – 516-326-1200
Award Amount: $1,194,283.00
Abstract:
DESCRIPTION (provided by applicant): Ischemic Stroke continues to be a major cause of morbidity and mortality in the United States. Currently approved thrombolytic therapy suffers for a narrow therapeutic window and clearly other therapeutic strategies areneeded, such as neuroprotective or… More

Retinoic Acid Modulation for Scleroderma

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bert J. Oehlen – 516-326-1200
Award Amount: $298,114.00
Abstract:
DESCRIPTION (provided by applicant): Systemic sclerosis (SSc) or diffuse scleroderma is a complex, chronic, autoimmune, connective tissue disease which primarily causes skin thickening and hardening in addition to interstitial fibrosis of lungs, gastrointestinal tract and arteries. Estimates of the… More

LPA Antagonists for the Treatment of IPF

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Weizhong Cai – 516-326-1200
Award Amount: $354,104.00
Abstract:
DESCRIPTION (provided by applicant): Idiopathic pulmonary fibrosis (IPF) is a progressive, agonizing, debilitating and routinely fatal disease that afflicts 200,000 individuals in the United States and five million patients worldwide. There are currentlyno effective treatments available for this… More

An Innovative Cardioprotective

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Prakash Narayan – 516-326-1200
Award Amount: $373,934.00
Abstract:
DESCRIPTION (provided by applicant): Myocardial infarction (MI) is a significant cause of morbidity and mortality in the U.S. H2 Relaxin (H2R) is a Phase III clinical trial-stage peptide that exhibits both anti-inflammatory and cytoprotective activities which can potentially be harnessed for the… More

A collagen wound dressing augmented with a proteoglycan mimic to enhance chronic

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bert J. Oehlen – 516-326-1200
Award Amount: $251,048.00
Abstract:
DESCRIPTION (provided by applicant): Liver fibrosis is a form of scar formation that is found in almost all patients with chronic injury to the liver. Over time it frequently progresses to cirrhosis, an end-stage lethal disease which is the seventh leadingcause of death in the United States and… More

Aldosterone Synthase Inhibitor for CKD

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bert J. Oehlen – 516-326-1200
Award Amount: $380,911.00
Abstract:
DESCRIPTION (provided by applicant): The renin-angiotensin-aldosterone system (RAAS) plays a critical role in renal physiology. Inhibitors of angiotensin-converting enzyme (ACE) or angiotensin receptor blockers (ARB) are the mainstay in the clinical management of renal disorders such as chronic… More